

## IMI2 - Call 15 webinar: Antimicrobial Resistance Accelerator - Pillar B (Tuberculosis Drug Development Network)



First Name	Last Name	Email	Country	Organization	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Jose	Ainsa	ainsa@unizar.es	Spain	Universidad de Zaragoza	Expertise in collaborative projects on tuberculosis drug discovery
Tatum	Anderson	tatumnanderson@gmail.com	United Kingdom	UK	Interest from researchers all over the world, policyholders and other readers
Emmanuel	André	emmanuel.andre@uzleuven.be	Belgium	KU Leuven	High throughput (1) automated BSL3 lab allowing testing and reading of microdilution plates (2) Automated WGS (3) New compounds
Viridiana	Beltran	viridiana.beltran.venegas@bbmri-eric.eu	Austria	BBMRI-ERIC	
Arantzazu	Blanco	ablanco@kveloce.com	Spain	KVeloce	Networking opportunities, since I work for a SME that brings together partners to build consortiums.
Amanda	Borens	aborens@c-path.org	United States	Critical Path Institute	
Gerry	Davies	gerrydavies@doctors.org.uk	United Kingdom	University of Liverpool	ex-coordinator of PreDiCT-TB, Phase I capability, statistical expertise in PK-PD and meta-analysis
Remco	De vrueh	remco.devrueth@lygature.org	Netherlands	Lygature	Partnership management, stakeholder engagement, project management
Elena	del Rey	edelrey@synapse-managers.com	Spain	SYNAPSE RESEARCH MANAGEMENT PARTNERS	
Neeraj	Dhar	neeraj.dhar@epfl.ch	Switzerland	EPFL	
Carlos	Diaz	cdiaz@synapse-managers.com	Spain	SYNAPSE RESEARCH MANAGEMENT PARTNERS	
Lanfranco	Fattorini	lanfranco.fattorini@iss.it	Italy	Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy	Twenty years of research and institutional activities on tuberculosis, particularly drug activity against M. tuberculosis
Maria	Garcia	maria.garcia@eurovertice.eu	Spain	Eurovertice	Support the participation of Catholic University of Murcia UCAM, and its principal investigator Horacio Pérez
Sandeep	Ghorpade	sandeep.ghorpade@uct.ac.za	South Africa	H3D, University of Cape Town	Medicinal chemist experienced in TB drug discovery
Federico	Giannoni	federico.giannoni@iss.it	Italy	Istituto Superiore di Sanità	Our group is expert on testing drugs and drug combinations in different Mtb growth conditions, and on studies of persistence
Jonathan	Gomez-Raja	jgomezraja@gmail.com	Spain	FundeSalud, Government of Extremadura	hospitals, patients and researchers
concepcion	gonzalez-bello	concepcion.gonzalez.bello@usc.es	Spain	University of Santiago de Compostela, CIQUS	
Wim-Jan	Koot	wim-jan.koot@lygature.org	Netherlands	Lygature	Project/Partnership Management, Data Management, Regulatory Expertise, Patient Engagement (in short:partnership infrastructure)
Roser	Mias	roser.mias@ciberes.org	Spain	CIBERES- Network Centre of Biomedical Research in respiratory diseases	
Kristina	Orrling	Kristina.Orrling@lygature.org	Netherlands	Lygature	Public-private partnership management, stakeholder engagement, regulatory innovation, public/patient involvement, communication
Annabel	Parret	parret@embl-hamburg.de	Germany	EMBL-Hamburg	Integrative structural biology of mycobacterial proteins
Santiago	Ramon Garcia	santiramon@unizar.es	Spain	ARAID Foundation	
Juan	Riese	jriese@eu-isciii.es	Spain	National Health Institute 'Carlos III'	As NCP for Horizon 2020 SC1 I promote participation to IMI2 calls. Knowledge about call details is critical for proper advice.

Edgars	Suna	edgars@osi.lv	Latvia	Latvian Institute of Organic Synthesis	medicinal chemistry (hit-to-lead and lead-to-CD), in-vivo pharmacology, bioanalytical support
Juan Jose	Vaquero	juanjose.vaquero@uc3m.es	Spain	Universidad Carlos III de Madrid	Quantitative preclinical imaging, clinical imaging biomarkers quantification, biomedical imaging technologies, proj. management
Cristina	Velasco	mariacristina.velasco@uc3m.es	Spain	UNIVERSIDAD CARLOS III DE MADRID	Administrative and financial advise
Michel	Vierboom	vierboom@bprc.nl	Netherlands	Biomedical Primate Research Centre	Well defined nonhuman primate models of TB, extensive platform for immunological evaluation, Imaging modality (PET/CT) for TB
Gerald	Voss	gerald.h.voss@gmail.com	Netherlands	TBVI	
Behrooz	Yousefi	b.yousefi@tum.de	Germany	089 4140 6493	
Andrea	Zaliani	andrea.zaliani@ime.fraunhofer.de	Germany	Fraunhofer IME	Medicinal Chemistry, Data Management, Data Science and Statistics